Charles River Laboratories International, Inc. (NYSE:CRL) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Charles River Laboratories, with 12 buys, three holds and one sell among 16 analysts. The average 12-month price target is $255.65, below the reported $289.40 share price.
• The company exceeded quarterly expectations, reporting $3.02 in adjusted EPS versus the $2.77 consensus and $1.00 billion in revenue versus $980.53 million expected. However, revenue declined 2.7% year over year, and management guided to fiscal 2026 EPS of $11.15–$11.45.
• Insiders have been selling shares: executives sold 165,990 shares worth approximately $42.6 million over the past 90 days, while institutional investors continue to own a dominant 98.91% of the company.

Shares of Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) have earned an average recommendation of "Moderate Buy" from the sixteen analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and twelve have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $255.6471.

Several equities analysts recently commented on the company. Barclays restated an "overweight" rating and set a $300.00 target price on shares of Charles River Laboratories International in a research report on Wednesday, August 5th. BNP Paribas Exane set a $250.00 price target on Charles River Laboratories International in a research report on Wednesday, July 1st. Evercore reissued an "outperform" rating on shares of Charles River Laboratories International in a report on Wednesday, August 5th. Piper Sandler set a $300.00 price objective on shares of Charles River Laboratories International in a research report on Monday, August 10th. Finally, Citigroup reaffirmed a "buy" rating on shares of Charles River Laboratories International in a research note on Wednesday, July 8th.

Charles River Laboratories International Stock Performance

CRL stock opened at $289.40 on Friday. The firm has a market cap of $13.82 billion, a PE ratio of -59.67, a P/E/G ratio of 2.88 and a beta of 1.40. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92. The business has a 50 day moving average of $255.01 and a 200-day moving average of $201.46. Charles River Laboratories International has a 12-month low of $144.26 and a 12-month high of $303.30.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. During the same period last year, the business posted $3.12 earnings per share. The business's revenue for the quarter was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, sell-side analysts expect that Charles River Laboratories International will post 11.33 earnings per share for the current year.

Insider Transactions at Charles River Laboratories International

In related news, EVP Shannon M. Parisotto sold 5,046 shares of the stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $263.00, for a total value of $1,327,098.00. Following the transaction, the executive vice president owned 4,807 shares of the company's stock, valued at $1,264,241. This represents a 51.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Birgit Girshick sold 6,500 shares of Charles River Laboratories International stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total value of $1,819,350.00. Following the sale, the chief executive officer directly owned 36,013 shares of the company's stock, valued at approximately $10,080,038.70. This trade represents a 15.29% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 165,990 shares of company stock worth $42,606,388. Company insiders own 1.30% of the company's stock.

Institutional Trading of Charles River Laboratories International

Hedge funds have recently bought and sold shares of the company. Continuum Advisory LLC bought a new position in Charles River Laboratories International during the second quarter valued at approximately $30,000. Los Angeles Capital Management LLC bought a new stake in shares of Charles River Laboratories International in the 4th quarter worth approximately $42,000. Sfam LLC bought a new stake in shares of Charles River Laboratories International in the 4th quarter worth approximately $43,000. Geneos Wealth Management Inc. boosted its stake in shares of Charles River Laboratories International by 98.0% in the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company's stock valued at $44,000 after purchasing an additional 145 shares in the last quarter. Finally, Elyxium Wealth LLC purchased a new stake in shares of Charles River Laboratories International in the 4th quarter valued at $46,000. Institutional investors own 98.91% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source